In India, BDR Pharmaceuticals has introduced BDENZA, an oral solution containing 32 mg/mL for the treatment of prostate cancer. This novel formulation, which costs Rs. 27,000 for 150mL, provides a more effective dosage form with fewer side effects than the current oral forms of enzalutamide. An important benefit of the oral solution is that it allows for dose reduction based on patient tolerance. This flexibility in modifying the regimen based on consumption volume is something that the current oral Enzalutamide dosage forms do not offer.
According to the World Health Organization, there are about 1.2 million new cases of prostate cancer diagnosed worldwide each year, which results in an estimated 375,000 deaths. It went from being the eighth most common cancer in Indian men in the 1990s to the third most common by 2015. 37,416 cases were reported in 2016, and by 2025, that number is expected to exceed 47,000. High dosage medications present difficulties because an elderly population makes up a large portion of those affected. BDR Pharmaceuticals has launched BDENZA, an oral solution that aims to address these issues by providing prostate cancer patients with improved adaptability and fewer side effects.
BDR Pharmaceuticals provides BDENZA ORAL SOLUTION, an inexpensive alternative medication formulation for the treatment of prostate cancer, in response to the difficulties faced by elderly patients. This creative solution eliminates the hassle of taking multiple pills by providing a powerful 160mg dose in a tiny 5ml serving. Unlike tablets with set dosages, physicians can alter the dosage for each patient. The sugar-free, pleasant-tasting oral solution is stomach-friendly, reducing the likelihood of side effects like nausea, and improves patient adherence—especially for patients who have dietary restrictions or taste changes. The introduction attempts to give patients with prostate cancer better treatment experiences and results.
According to Dr. Aravind Badiger, Director of Technical Formulation, BDENZA ORAL SOLUTION substantially improves patient compliance by providing a more straightforward and patient-friendly approach to treating prostate cancer. With the goal of enhancing patient experience and adherence to prostate cancer treatment, this oral solution offers patients a more flexible and convenient option.
BDENZA ORAL SOLUTION represents a significant breakthrough in the treatment of prostate cancer, offering millions of patients worldwide comfort and hope. BDENZA, which has been called a paradigm shift, is consistent with the business’s dedication to providing affordable, patient-centered healthcare solutions. This novel oral solution tackles issues with ease of use, less adverse effects, a tasty sugar-free flavor, and affordability. Director of Business Development for the BDR Group Raheel Shah highlights how BDENZA has had a major influence on changing and improving patient-friendly and accessible prostate cancer treatment.
